c-Myc hot spot mutations in lymphomas result in inefficient ubiquitination and decreased proteasome-mediated turnover

被引:222
作者
Bahram, F
von der Lehr, N
Cetinkaya, C
Larsson, LG
机构
[1] Swedish Univ Agr Sci, Dept Plant Biol, Uppsala Genet Ctr, S-75007 Uppsala, Sweden
[2] Univ Uppsala Hosp, Dept Genet & Pathol, Uppsala, Sweden
关键词
D O I
10.1182/blood.V95.6.2104
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The c-myc proto-oncogene encodes a short-lived transcription factor that plays an important role in cell cycle regulation, differentiation and apoptosis, c-myc is often rearranged in tumors resulting in deregulated expression. In addition, mutations in the coding region of c-myc are frequently found in human lymphomas, a hot spot being the Thr58 phosphorylation site, a mutation shown to enhance the transforming capacity of c-Myc, It Is, however, still unclear in what way this mutation affects c-Myc activity, Our resuits show that proteasome-mediated turnover of c-Myc is substantially impaired in Burkitt's lymphoma cells with mutated Thr58 or other mutations that abolish Thr58 phosphorylation, whereas endogenous or ectopically expressed wild type c-Myc proteins turn over at normal rates In these cells. Myc Thr58 mutants expressed ectopically in other cell types also exhibit reduced proteasome-mediated degradation, which correlates with a substantial decrease in their ubiquitination, These results suggest that ubiquitin/proteasome-mediated degradation of c-Myc is triggered by Thr58 phosphorylation revealing a new important level of control of c-Myc activity. Mutation of Thr58 in lymphoma thus escapes this regulation resulting In accumulation of c-Myc protein, likely as part of the tumor progression, (C) 2000 by The American Society of Hematology.
引用
收藏
页码:2104 / 2110
页数:7
相关论文
共 38 条
[1]   beta-catenin is a target for the ubiquitin-proteasome pathway [J].
Aberle, H ;
Bauer, A ;
Stappert, J ;
Kispert, A ;
Kemler, R .
EMBO JOURNAL, 1997, 16 (13) :3797-3804
[2]  
ALBERT T, 1994, ONCOGENE, V9, P759
[3]  
ALVAREZ E, 1991, J BIOL CHEM, V266, P15277
[4]   The amino-terminal phosphorylation sites of C-MYC are frequently mutated in Burkitt's lymphoma lines but not in mouse plasmacytomas and rat immunocytomas [J].
Axelson, H ;
Henriksson, M ;
Wang, Y ;
Magnusson, KP ;
Klein, G .
EUROPEAN JOURNAL OF CANCER, 1995, 31A (12) :2099-2104
[5]   Posttranslational regulation of Myc function in response to phorbol ester/interferon-γ-induced differentiation of v-Myc-transformed U-937 monoblasts [J].
Bahram, F ;
Wu, SQ ;
Öberg, F ;
Lüscher, B ;
Larsson, LG .
BLOOD, 1999, 93 (11) :3900-3912
[6]  
BHATIA K, 1994, BLOOD, V84, P883
[7]   POINT MUTATIONS IN THE C-MYC TRANSACTIVATION DOMAIN ARE COMMON IN BURKITTS-LYMPHOMA AND MOUSE PLASMACYTOMAS [J].
BHATIA, K ;
HUPPI, K ;
SPANGLER, G ;
SIWARSKI, D ;
IYER, R ;
MAGRATH, I .
NATURE GENETICS, 1993, 5 (01) :56-61
[8]   In vivo degradation of N-myc in neuroblastoma cells is mediated by the 26S proteasome [J].
Bonvini, P ;
Nguyen, P ;
Trepel, J ;
Neckers, LM .
ONCOGENE, 1998, 16 (09) :1131-1139
[9]   DEGRADATION OF NUCLEAR ONCOPROTEINS BY THE UBIQUITIN SYSTEM INVITRO [J].
CIECHANOVER, A ;
DIGIUSEPPE, JA ;
BERCOVICH, B ;
ORIAN, A ;
RICHTER, JD ;
SCHWARTZ, AL ;
BRODEUR, GM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (01) :139-143
[10]  
CLARK HM, 1994, CANCER RES, V54, P3383